Caring Brands 3Q 2026: Revenue $0, EPS ($0.08) — 10-Q Summary
Caring Brands (CABR) reported no revenue for 3Q 2026, down from $740K a year earlier. Net loss narrowed 19% to $827K, with operating expenses falling 30%. Professional service fees declined 69%, while payroll expenses rose 96%. No sales were recorded for Emesyl, and licensing revenue timing remains uncertain.
How this was made

The 30-second read
Why it matters
For traders, the key signal is the combination of $0 revenue and no Emesyl sales/royalties in the quarter, partially offset by reduced operating expenses and a narrower loss.
Market read
This is a company-specific quarterly disclosure that can influence valuation via near-term revenue expectations and commercialization progress.
What to watch
The expanded SanPellegrino agreement adds territories for Photocil and Hair Enzyme Booster, but the filing emphasizes revenue timing remains subject to regulatory and contractual considerations, which may explain the $0 revenue quarter.
Background
The piece is a brief summary of Caring Brands’ 10-Q filed Nov. 13, 2026, covering 3Q 2026 financials and commercialization/licensing updates.
Ticker impact
Caring Brands’ 10-Q summary shows $0 revenue in 3Q 2026 and a diluted EPS loss of ($0.08), with operating expenses down 30%.
Likely downward pressure or continued weakness as investors focus on the lack of Emesyl sales and $0 revenue, despite lower operating expenses.
The article’s primary new datapoints are the quarter’s $0 revenue and the absence of Emesyl commercialization activity, which directly affect revenue trajectory assumptions.
Market effects
Reinforces the high execution risk for small biopharma licensing/commercialization models when product sales are absent.
None indicated.
None indicated.
Counterpoint
The loss narrowing is driven by lower professional service fees, which could indicate cost discipline rather than deteriorating fundamentals, and licensing timing may be delayed rather than lost.
Key entities
- companyCaring Brands, Inc.
CABR, reported $0 revenue in the quarter, diluted EPS loss of ($0.08), and no Emesyl commercialization activity; also discussed expanded SanPellegrino agreement territories.



